Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more
Percheron Therapeutics Limited (PERCF) - Total Assets
Latest total assets as of June 2025: $12.44 Million USD
Based on the latest financial reports, Percheron Therapeutics Limited (PERCF) holds total assets worth $12.44 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Percheron Therapeutics Limited - Total Assets Trend (2022–2025)
This chart illustrates how Percheron Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Percheron Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Percheron Therapeutics Limited's total assets of $12.44 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.8% |
| Accounts Receivable | $59.95K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Percheron Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Percheron Therapeutics Limited's current assets represent 99.7% of total assets in 2025, an increase from 99.0% in 2022.
- Cash Position: Cash and equivalents constituted 81.8% of total assets in 2025, down from 85.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Percheron Therapeutics Limited Competitors by Total Assets
Key competitors of Percheron Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Percheron Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Percheron Therapeutics Limited generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Percheron Therapeutics Limited is currently not profitable relative to its asset base.
Percheron Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.10 | 2.81 | - |
| Quick Ratio | 5.10 | 2.81 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $9.97 Million | $ 9.32 Million | - |
Percheron Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Percheron Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -14.4% |
| Total Assets | $12.44 Million |
| Market Capitalization | $3.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Percheron Therapeutics Limited's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Percheron Therapeutics Limited's assets decreased by 14.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Percheron Therapeutics Limited (2022–2025)
The table below shows the annual total assets of Percheron Therapeutics Limited from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $12.44 Million | -14.41% |
| 2024-06-30 | $14.53 Million | +13.14% |
| 2023-06-30 | $12.84 Million | -42.76% |
| 2022-06-30 | $22.44 Million | -- |